Reports
Sale
Global Viral Vector Manufacturing Market Size, Share, Trends: By Vector Type: Retroviral Vectors, Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Others; By Indication Type; By Application; By Production System; By Production Scale; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Viral Vector Manufacturing Market Outlook
The global viral vector manufacturing market size was valued at USD 2.6 billion in 2023, driven by increased funding for gene therapy development. The market is expected to grow at a CAGR of 19.74% during the forecast period of 2024-2032, with the values likely to rise from USD 3.2 billion in 2024 to USD 13.5 billion by 2032.
Global Viral Vector Manufacturing Market Overview
Viral vectors are efficient gene transfer vehicles that are commonly used by molecular biologists to manipulate a specific cell type or tissue for certain therapeutic purposes. The viral vector manufacturing market is witnessing a steady rise due to increased research and development activities aimed at the early diagnosis and effective treatment of several medical conditions. In April 2023, a study published in the New England Journal of Medicine revealed the genetic cause of severe developmental diseases in about 5,500 patients. With a rise in the prevalence of genetic disorders along with technical advancements in diagnostic methods, the viral vector manufacturing market demand is expected to fuel in the coming years.
Several leading players in the market are actively investing in the capacity expansion for viral vector manufacturing activities. In June 2023, SK Inc.'s subsidiary SK Pharmteco, a global contract development and manufacturing organization headquartered in California, announced the establishment of its second facility for cell and gene therapies (CGT) manufacturing in Europe spanning 5000 square meters. The new facility specializes in the bioproduction of lentiviral vectors (LV) and adeno-associated virus (AAV). With the help of its commercial viral vector manufacturing subsidiary for CGTs, the company is expanding its presence in the market. The surge in investments to scale up viral vector production are anticipated to propel the viral vector manufacturing market growth in the forecast period.
The market is also driven by the rise in government initiatives and programs to fuel viral vector manufacture and development. The rising healthcare expenditure to improve patient outcomes is another factor, poised to aid expansion of the market size.
Global Viral Vector Manufacturing Market Trends
| Key Trends | Description |
| Increased Investment in Gene Therapy | With rising interest in gene therapy for treating genetic disorders, investment in viral vector manufacturing is growing. This includes funding for research, development, and scaling production capabilities. |
| Advances in Production Technologies | Technological improvements in bioreactors and downstream processing are enhancing yield and purity. These advances reduce costs for viral vector-based therapies. |
| Regulatory Evolutions | Regulatory health agencies are adapting frameworks to ensure the safety and efficacy of viral vector-based treatments. In addition, rapid approval processes for gene therapies and vaccines are positively impacting market dynamics. |
| Expansion into Emerging Markets | Companies are expanding their geographic presence to tap into emerging markets, where there's a growing demand for advanced therapeutics. This includes establishing manufacturing facilities and partnerships in these regions. |
Global Viral Vector Manufacturing Market Segmentation
Market Breakup by Vector Type
- Retroviral Vectors
- Lentiviral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral (AAV) Vectors
- Herpes Simplex Viral (HSV) Vectors
- Vaccinia Viral Vectors
- Others
The market is segmented by vector type into retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral (AAV) vectors, herpes simplex viral (HSV) vectors, vaccinia viral vectors, and others. This segmentation offers an overview of the various types of vectors used in gene therapy and research.
Market Breakup by Indication Type
- Cancer
- Genetic Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Others
By indication type, the market is segmented into cancer, genetic disorders, infectious diseases, cardiovascular diseases, neurological disorders, and others. This market segment elucidates the applications of viral vector manufacturing across various medical conditions. Cancer stands as a prominent indication, with viral vectors utilized in gene therapy approaches targeting tumor cells. This segmentation reflects the potential of viral technology for effective therapeutic intervention, which is poised to boost the viral vector manufacturing market share in the forecast period.
Market Breakup by Application
- Gene Therapy
- Vaccinology
- Drug Discovery and Development
- Others
Applications of the market include gene therapy, vaccinology, drug discovery and development, and others. This segmentation highlights the diverse uses of viral vectors across different medical and scientific fields.
Market Breakup by Production System
- Baculovirus Expression System
- Mammalian Cell Expression System
- Insect Cell Expression System
- Others
The market breakup by production system includes the baculovirus expression system, mammalian cell expression system, insect cell expression system, and others. Each production system offers a set of unique advantages. These systems are selected based on factors such as scalability, efficiency, and downstream processing requirements in viral vector manufacturing.
Market Breakup by Production Scale
- Large-Scale Production
- Mid-Scale Production
- Small-Scale Production
The viral vector manufacturing market report also includes breakup by production scale as well. It comprises large-scale production, mid-scale production, and small-scale production. The various production capacities are aligned to specific market demands and applications to ensure efficient and cost-effective viral vector manufacturing.
Market Breakup by End User
- Biopharmaceutical Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Research Institutes
- Others
End users of the market are biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutes, and others. This segmentation reflects the range of users that contribute to the market of viral vector manufacturing.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market breakup by region covers several major markets including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is dominating the market share which can be attributed to the presence of key pharmaceutical and biotechnology companies, research facilities, and a robust healthcare infrastructure in the region.
Global Viral Vector Manufacturing Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- Catalent, Inc.
- Merck KGaA (MilliporeSigma)
- FUJIFILM Diosynth Biotechnologies
- WuXi AppTec Co., Ltd.
- Cobra Biologics (Acquired by Pall Corporation)
- VGXI, Inc.
- Sartorius AG
- Kaneka Eurogentec S.A.
- Vigene Biosciences, Inc.
- Oxford Biomedica plc
- Cell and Gene Therapy Catapult
- Rentschler Biopharma SE
- 4D Molecular Therapeutics
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Vector Type |
|
| Breakup by Indication Type |
|
| Breakup by Application |
|
| Breakup by Production System |
|
| Breakup by Production Scale |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Global Viral Vector Manufacturing Market Report
- How is the market landscape expected to evolve in the coming years?
- What are the major trends influencing the market?
- What are the significant drivers, opportunities, and restraints in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which country is poised to lead the market share in the forecast period?
- Which country is expected to witness rapid growth during the forecast period?
- Which vector types are expected to dominate the respective market segment?
- Which indication type will result in the expansion of viral vector manufacturing market size?
- Which applications are expected to impact the growth of the market significantly?
- Which production system will dominate the market in the forecast period?
- What are the key research initiatives expected to boost the market value during the forecast period?
- Which type of production scale has high demand in the market?
- What major companies are involved in the supplier landscape of the market?
- How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Viral Vector Manufacturing Market Overview
3.1 Global Viral Vector Manufacturing Market Historical Value (2017-2023)
3.2 Global Viral Vector Manufacturing Market Forecast Value (2024-2032)
4 Global Viral Vector Manufacturing Market Landscape*
4.1 Global Viral Vector Manufacturing: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Viral Vector Manufacturing: Product Landscape
4.2.1 Analysis by Vector Type
4.2.2 Analysis by Indication Type
5 Global Viral Vector Manufacturing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Viral Vector Manufacturing Market Segmentation (2017-2032)
6.1 Global Viral Vector Manufacturing Market (2017-2032) by Vector Type
6.1.1 Market Overview
6.1.2 Retroviral Vectors
6.1.3 Lentiviral Vectors
6.1.4 Adenoviral Vectors
6.1.5 Adeno-Associated Viral (AAV) Vectors
6.1.6 Herpes Simplex Viral (HSV) Vectors
6.1.7 Vaccinia Viral Vectors
6.1.8 Others
6.2 Global Viral Vector Manufacturing Market (2017-2032) by Indication Type
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Genetic Disorders
6.2.4 Infectious Diseases
6.2.5 Cardiovascular Diseases
6.2.6 Neurological Disorders
6.2.7 Others
6.3 Global Viral Vector Manufacturing Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Gene Therapy
6.3.3 Vaccinology
6.3.4 Drug Discovery and Development
6.3.5 Others
6.4 Global Viral Vector Manufacturing Market (2017-2032) by Production System
6.4.1 Market Overview
6.4.2 Baculovirus Expression System
6.4.3 Mammalian Cell Expression System
6.4.4 Insect Cell Expression System
6.4.5 Others
6.5 Global Viral Vector Manufacturing Market (2017-2032) by Production Scale
6.5.1 Market Overview
6.5.2 Large-Scale Production
6.5.3 Mid-Scale Production
6.5.4 Small-Scale Production
6.6 Global Viral Vector Manufacturing Market (2017-2032) by End User
6.6.1 Market Overview
6.6.2 Biopharmaceutical Companies
6.6.3 Contract Development and Manufacturing Organizations (CDMOs)
6.6.4 Research Institutes
6.6.5 Others
6.7 Global Viral Vector Manufacturing Market (2017-2032) by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Viral Vector Manufacturing Market (2017-2032)
7.1 North America Viral Vector Manufacturing Market (2017-2032) by Vector Type
7.1.1 Market Overview
7.1.2 Retroviral Vectors
7.1.3 Lentiviral Vectors
7.1.4 Adenoviral Vectors
7.1.5 Adeno-Associated Viral (AAV) Vectors
7.1.6 Herpes Simplex Viral (HSV) Vectors
7.1.7 Vaccinia Viral Vectors
7.1.8 Others
7.2 North America Viral Vector Manufacturing Market (2017-2032) by Indication Type
7.2.1 Market Overview
7.2.2 Cancer
7.2.3 Genetic Disorders
7.2.4 Infectious Diseases
7.2.5 Cardiovascular Diseases
7.2.6 Neurological Disorders
7.2.7 Others
7.3 North America Viral Vector Manufacturing Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Viral Vector Manufacturing Market (2017-2032)
8.1 Europe Viral Vector Manufacturing Market (2017-2032) by Vector Type
8.1.1 Market Overview
8.1.2 Retroviral Vectors
8.1.3 Lentiviral Vectors
8.1.4 Adenoviral Vectors
8.1.5 Adeno-Associated Viral (AAV) Vectors
8.1.6 Herpes Simplex Viral (HSV) Vectors
8.1.7 Vaccinia Viral Vectors
8.1.8 Others
8.2 Europe Viral Vector Manufacturing Market (2017-2032) by Indication Type
8.2.1 Market Overview
8.2.2 Cancer
8.2.3 Genetic Disorders
8.2.4 Infectious Diseases
8.2.5 Cardiovascular Diseases
8.2.6 Neurological Disorders
8.2.7 Others
8.3 Europe Viral Vector Manufacturing Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Viral Vector Manufacturing Market (2017-2032)
9.1 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Vector Type
9.1.1 Market Overview
9.1.2 Retroviral Vectors
9.1.3 Lentiviral Vectors
9.1.4 Adenoviral Vectors
9.1.5 Adeno-Associated Viral (AAV) Vectors
9.1.6 Herpes Simplex Viral (HSV) Vectors
9.1.7 Vaccinia Viral Vectors
9.1.8 Others
9.2 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Indication Type
9.2.1 Market Overview
9.2.2 Cancer
9.2.3 Genetic Disorders
9.2.4 Infectious Diseases
9.2.5 Cardiovascular Diseases
9.2.6 Neurological Disorders
9.2.7 Others
9.3 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Viral Vector Manufacturing Market (2017-2032)
10.1 Latin America Viral Vector Manufacturing Market (2017-2032) by Vector Type
10.1.1 Market Overview
10.1.2 Retroviral Vectors
10.1.3 Lentiviral Vectors
10.1.4 Adenoviral Vectors
10.1.5 Adeno-Associated Viral (AAV) Vectors
10.1.6 Herpes Simplex Viral (HSV) Vectors
10.1.7 Vaccinia Viral Vectors
10.1.8 Others
10.2 Latin America Viral Vector Manufacturing Market (2017-2032) by Indication Type
10.2.1 Market Overview
10.2.2 Cancer
10.2.3 Genetic Disorders
10.2.4 Infectious Diseases
10.2.5 Cardiovascular Diseases
10.2.6 Neurological Disorders
10.2.7 Others
10.3 Latin America Viral Vector Manufacturing Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Viral Vector Manufacturing Market (2017-2032)
11.1 Middle East and Africa Viral Vector Manufacturing Market (2017-2032) by Vector Type
11.1.1 Market Overview
11.1.2 Retroviral Vectors
11.1.3 Lentiviral Vectors
11.1.4 Adenoviral Vectors
11.1.5 Adeno-Associated Viral (AAV) Vectors
11.1.6 Herpes Simplex Viral (HSV) Vectors
11.1.7 Vaccinia Viral Vectors
11.1.8 Others
11.2 Middle East and Africa Viral Vector Manufacturing Market (2017-2032) by Indication Type
11.2.1 Market Overview
11.2.2 Cancer
11.2.3 Genetic Disorders
11.2.4 Infectious Diseases
11.2.5 Cardiovascular Diseases
11.2.6 Neurological Disorders
11.2.7 Others
11.3 Middle East and Africa Viral Vector Manufacturing Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Lonza Group AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Thermo Fisher Scientific Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Catalent, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Merck KGaA (MilliporeSigma)
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 FUJIFILM Diosynth Biotechnologies
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 WuXi AppTec Co., Ltd.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Cobra Biologics (Acquired by Pall Corporation)
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 VGXI, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Sartorius AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Kaneka Eurogentec S.A.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Vigene Biosciences, Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Oxford Biomedica plc
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Cell and Gene Therapy Catapult
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Rentschler Biopharma SE
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 4D Molecular Therapeutics
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Viral Vector Manufacturing Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 2.6 billion in 2023 driven by driven by increased funding for gene therapy development across the globe.
The market is anticipated to grow at a CAGR of 19.74% during the forecast period of 2024-2032, likely to reach a market value of USD 13.5 billion by 2032.
The rising prevalence of genetic disorders along with the growing impetus on the development of novel therapeutics are fuelling the demand for the market.
One of the significant trends in the market is the rising investment in capacity expansion for viral vector manufacturing activities. In June 2023, SK Inc.'s subsidiary SK Pharmteco, announced the establishment of its second facility for cell and gene therapies (CGT) manufacturing in Europe spanning 5000 square meters.
Based on the vector type, the market is segmented into retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral (AAV) vectors, herpes simplex viral (HSV) vectors, vaccinia viral vectors, and others.
By indication type, the market is segmented into cancer, genetic disorders, infectious diseases, cardiovascular diseases, neurological disorders, and others.
Various production systems include the baculovirus expression system, mammalian cell expression system, insect cell expression system, and others.
Based on the production scale, the market is segmented into large-scale production, mid-scale production, and small-scale production.
End users of the market are biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutes, and others.
Common application areas include gene therapy, vaccinology, drug discovery and development, and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Lonza Group AG, Thermo Fisher Scientific Inc., Catalent, Inc., Merck KGaA (MilliporeSigma), FUJIFILM Diosynth Biotechnologies, WuXi AppTec Co., Ltd., Cobra Biologics (Acquired by Pall Corporation), VGXI, Inc., Sartorius AG, Kaneka Eurogentec S.A., Vigene Biosciences, Inc., Oxford Biomedica plc, Cell and Gene Therapy Catapult, Rentschler Biopharma SE, and 4D Molecular Therapeutics.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER